• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jerome Ritz, MD


  • Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, Stevenson K, Ritz J, Neuberg D, Brusic V, Gabriel S, Lander ES, Getz G, Hacohen N, Wu CJ.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Blood. 2014 Jul 17(3):453-62.
  • Socié G, Ritz J.Current issues in chronic graft-versus-host disease.Blood. 2014 Jun 9.
  • Koreth J, Kim HT, Nikiforow S, Milford EL, Armand P, Cutler C, Glotzbecker B, Ho VT, Antin JH, Soiffer RJ, Ritz J, Alyea EP.Donor Chimerism Early after Reduced-intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival.Biol Blood Marrow Transplant. 2014 Jun 4.
  • Murase K, Kim HT, Bascug OR, Kawano Y, Ryan J, Matsuoka KI, Davids MS, Koreth J, Ho VT, Cutler C, Armand P, Alyea EP, Blazar BR, Antin JH, Soiffer RJ, Letai A, Ritz J.Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.Haematologica. 2014 May 23.
  • Flynn R, Du J, Veenstra RG, Reichenbach DK, Panoskaltsis-Mortari A, Taylor PA, Freeman GJ, Serody JS, Murphy WJ, Munn DH, Sarantopoulos S, Luznik L, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Dubovsky JA, Byrd JC, Macdonald KP, Hill GR, Blazar BR.Increased T follicular helper cells and germinal center B cells are required for chronic GVHD (cGVHD) and bronchiolitis obliterans.Blood. 2014 May 12.
  • Ueno S, Lu J, He J, Li A, Zhang X, Ritz J, Silberstein LE, Chai L.Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: Mechanism, function, and implication for a potential novel therapeutic target.Exp Hematol. 2014 Apr;42(4):307-316.e8.
  • Jacobson CA, Sun L, Kim HT, McDonough SM, Reynolds CG, Schowalter M, Koreth J, Cutler CS, Ho VT, Alyea EP, Armand P, Blazar BR, Soiffer RJ, Antin JH, Ritz J, Sarantopoulos S.Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2014 May;20(5):668-75.
  • Gazourian L, Rogers AJ, Ibanga R, Weinhouse GL, Pinto-Plata V, Ritz J, Soiffer RJ, Antin JH, Washko GR, Baron RM, Ho VT.Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.Am J Hematol. 2014 Apr;89(4):404-9.
  • Kim HT, Frederick D, Armand P, Andler E, Kao G, Cutler C, Koreth J, Alyea EP, Antin JH, Soiffer RJ, Ritz J, Ho VT.White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.Am J Hematol. 2014 Feb 18.
  • Bachireddy P, Hainz U, Rooney M, Pozdnyakova O, Aldridge J, Zhang W, Liao X, Hodi FS, O'Connell K, Haining WN, Goldstein NR, Canning CM, Soiffer RJ, Ritz J, Hacohen N, Alyea EP, Kim HT, Wu CJ.Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.Blood. 2014 Feb 27;123(9):1412-21.
  • Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, Pelus LM, Desponts C, Chen YB, Rezner B, Armand P, Koreth J, Glotzbecker B, Ho VT, Alyea E, Isom M, Kao G, Armant M, Silberstein L, Hu P, Soiffer RJ, Scadden DT, Ritz J, Goessling W, North TE, Mendlein J, Ballen K, Zon LI, Antin JH, Shoemaker DD.Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.Blood. 2013 Oct 24;122(17):3074-81.
  • Koreth J, Ritz J.Tregs, HSCT, and acute GVHD: up close and personal.Blood. 2013 Sep 5;122(10):1690-1.
  • Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Sievers QL, Brusic A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.J Clin Invest. 2013 Sep 3;123(9):3756-65.
  • Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, Rosenblatt J, McDonough S, Watanaboonyongcharoen P, Armand P, Koreth J, Glotzbecker B, Alyea E, Blazar BR, Soiffer RJ, Ritz J, Antin JH.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Blood. 2013 Aug 22;122(8):1510-7.
  • Vander Lugt MT, Braun TM, Hanash S, Ritz J, Ho VT, Antin JH, Zhang Q, Wong CH, Wang H, Chin A, Gomez A, Harris AC, Levine JE, Choi SW, Couriel D, Reddy P, Ferrara JL, Paczesny S.ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death.N Engl J Med. 2013 Aug 8;369(6):529-39.
  • Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia / small lymphocytic lymphoma.Haematologica. 2013 May 3.
  • Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP, Blazar BR, Ritz J, Soiffer RJ, Antin JH, Cutler CS.Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.Biol Blood Marrow Transplant. 2013 May;19(5):804-11.
  • Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J.Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.Sci Transl Med. 2013 Apr 3;5(179):179ra43.
  • Hu D, Weiner HL, Ritz J.Identification of Cytolytic CD161(-)CD56(+) Regulatory CD8 T Cells in Human Peripheral Blood.PLoS ONE. 2013;8(3):e59545.
  • Li P, Stratton ZS, Dao M, Ritz J, Huang TJ.Probing circulating tumor cells in microfluidics.Lab Chip. 2013 Feb 21;13(4):602-9.
  • Gazourian L, Coronata AM, Rogers AJ, Weinhouse GL, Soiffer RJ, Antin JH, Ritz J, Ho VT, Baron RM, Washko GR.Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.Respiratory Medicine. 2013 Feb;107(2):276-83.
  • Brusic A, Hainz U, Wadleigh M, Neuberg D, Su M, Canning CM, Deangelo DJ, Stone RM, Lee JS, Mulligan RC, Ritz J, Dranoff G, Sasada T, Wu CJ.Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients.Oncoimmunology. 2012 Oct 1;1(7):1095-1103.
  • Allen JL, Fore MS, Wooten J, Roehrs PA, Bhuiya NS, Hoffert T, Sharf A, Deal AM, Armistead P, Coghill J, Gabriel DA, Irons R, Essenmacher A, Shea TC, Richards K, Cutler C, Ritz J, Serody J, Baldwin AS, Sarantopoulos S.B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.Blood. 2012 Sep 20;120(12):2529-36.
  • Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP.Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.J Clin Oncol. 2012 Sep 10;30(26):3202-8.
  • Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT.A disease risk index for patients undergoing allogeneic stem cell transplantation.Blood. 2012 Jul 26;120(4):905-13.
  • Chen YB, McDonough S, Hasserjian R, Chen H, Coughlin E, Illiano C, Park IS, Jagasia M, Spitzer TR, Cutler CS, Soiffer RJ, Ritz J.Expression of CD30 in patients with acute graft-versus-host disease.Blood. 2012 Jul 19;120(3):691-6.
  • Bellucci R, Nguyen HN, Martin A, Heinrichs S, Schinzel AC, Hahn WC, Ritz J.Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells.J Clin Invest. 2012 Jul 2;122(7):2369-83.
  • Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ.Interleukin-2 and regulatory T cells in graft-versus-host disease.N Engl J Med. 2011 Dec 1;365(22):2055-66.
  • Melanson SE, Stevenson K, Kim H, Antin JH, Court MH, Ho VT, Ritz J, Soiffer RJ, Kuo FC, Longtine JA, Jarolim P.Response to helsby and tingle.Am J Hematol. 2011 Apr;86(4):384.
  • Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, Neuberg D, Wucherpfennig KW, Brown JR, Novina CD.MicroRNA Expression Profiling Identifies Activated B Cell Status in Chronic Lymphocytic Leukemia Cells.PLoS ONE. 2011;6(3):e16956.
  • Lin Y, Zhang L, Cai AX, Lee M, Zhang W, Neuberg D, Canning CM, Soiffer RJ, Alyea EP, Ritz J, Hacohen N, Means TK, Wu CJ.Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans.J Clin Invest. 2011 Mar 14.
  • Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, Alyea EP, Ho VT, Soiffer RJ, Antin JH, Ritz J.Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.Blood. 2011 Feb 17;117(7):2275-83.
  • Ho VT, Kim HT, Aldridge J, Liney D, Kao G, Armand P, Koreth J, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP.Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2010 Dec 27.
  • Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA.Viral induction and targeted inhibition of galectin-1 in EBV+ post-transplant lymphoproliferative disorders.Blood. 2011 Feb 7.
  • Nombela-Arrieta C, Ritz J, Silberstein LE.The elusive nature and function of mesenchymal stem cells.Nat Rev Mol Cell Biol. 2011 Feb;12(2):126-31.
  • Melanson SE, Stevenson K, Kim H, Antin JH, Court MH, Ho VT, Ritz J, Soiffer RJ, Kuo FC, Longtine JA, Jarolim P.Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.Am J Hematol. 2010 Dec;85(12):967-71.
  • Jacobson CA, Ritz J.B-cell-directed therapy for chronic graft-versus-host disease.Haematologica. 2010 Nov;95(11):1811-3.
  • Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K.Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.Bone Marrow Transplant. 2010 Aug 9.
  • Kao GS, Kim HT, Daley H, Ritz J, Burger SR, Kelley L, Vierra-Green C, Flesch S, Spellman S, Miller J, Confer D.Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products.Transfusion. 2010 Jul 1.
  • Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, Ho V, Alyea E, Koreth J, Armand P, Soiffer R, Ritz J, Richardson PG, Antin JH.Prediction Of Veno-Occlusive Disease Using Biomarkers Of Endothelial Injury.Biol Blood Marrow Transplant. 2010 Aug;16(8):1180-5.
  • Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, Reynolds C, Herrera M, Liney D, Ho V, Kao G, Armand P, Koreth J, Alyea E, McAfee S, Attar E, Dey B, Spitzer T, Soiffer R, Ritz J, Antin JH, Boussiotis VA.Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.Blood. 2010 May 20;115(20):4111-9.
  • Zhang W, Choi J, Zeng W, Rogers SA, Alyea EP, Rheinwald JG, Canning CM, Brusic V, Sasada T, Reinherz EL, Ritz J, Soiffer RJ, Wu CJ.Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.Clin Cancer Res. 2010 May 15;16(10):2729-39.
  • Koreth J, Aldridge J, Kim HT, Alyea EP, Cutler C, Armand P, Ritz J, Antin JH, Soiffer RJ, Ho VT.Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced Age.Biol Blood Marrow Transplant. 2010 Jun;16(6):792-800.
  • Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J.Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.J Clin Invest. 2010 May 3;120(5):1479-93.
  • Miller JS, Warren EH, Vandenbrink MR, Ritz J, Shlomchik WD, Murphy WJ, Barrett AJ, Kolb HJ, Giralt S, Bishop MR, Blazar BR, Falkenburg JH.Nci 1st International Workshop On The Biology, Prevention, And Treatment Of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report From The Committee On The Biology Underlying Recurrence Of Malignant Disease Following Allogeneic Hsct: Graft-Versus-Tumor/Leukemia Reaction.Biol Blood Marrow Transplant. 2010 May;16(5):565-86.
  • Ofran Y, Kim HT, Brusic V, Blake L, Mandrell M, Wu CJ, Sarantopoulos S, Bellucci R, Keskin DB, Soiffer RJ, Antin JH, Ritz J.Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.Clin Cancer Res. 2010 Mar 1;16(5):1642-51.
  • Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, Duke-Cohan JS, Liu F, Brusic V, Neuberg D, Kutok JL, Alyea EP, Canning CM, Soiffer RJ, Ritz J, Wu CJ.Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.Cancer Res. 2010 Feb 15;70(4):1344-55.
  • Socie G, Ritz J, Martin PJ.Current challenges in chronic graft-versus-host disease.Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S146-51. Review.
  • Biernacki MA, Marina O, Zhang W, Liu F, Bruns I, Cai A, Neuberg D, Canning CM, Alyea EP, Soiffer RJ, Brusic V, Ritz J, Wu CJ.Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.Cancer Res. 2010 Feb 1;70(3):906-15.
  • Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7.
  • McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, Antin JH, Lee SJ, Ruutu T, Storer B, Warren EH, Zhang B, Zhao LP, Ginsburg D, Soiffer RJ, Partanen J, Hansen JA, Ritz J, Palotie A, Altshuler D.Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.Nat Genet. 2009 Dec;41(12):1341-4.
  • Patel NC, Chinen J, Rosenblatt HM, Hanson IC, Krance RA, Paul ME, Abramson SL, Noroski LM, Davis CM, Seeborg FO, Foster SB, Leung KS, Brown BS, Ritz J, Shearer WT.Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning.J Allergy Clin Immunol. 2009 Nov;124(5):1062-9.e1-4.
  • Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP.Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.Blood. 2009 Oct 29;114(18):3956-9.
  • Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, Cutler C, Koreth J, Alyea E, Sarantopoulos S, Antin JH, Ritz J, Canning C, Kutok J, Mihm MC, Dranoff G, Soiffer R.Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15825-30.
  • Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S, Spitzer TR, Soiffer R, Antin JH, Ritz J.Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2009 Sep;15(9):1066-76.
  • Wu CJ, Ritz J.Revealing tumor immunity after hematopoietic stem cell transplantation.Clin Cancer Res. 2009 Jul 15;15(14):4515-7.
  • Zorn E,Mohseni M,Kim H,Porcheray F,Lynch A,Bellucci R,Canning C,Alyea EP,Soiffer RJ,Ritz J.Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2009 Mar;15(3):382-8.
  • Sarantopoulos S,Stevenson KE,Kim HT,Cutler CS,Bhuiya NS,Schowalter M,Ho VT,Alyea EP,Koreth J,Blazar BR,Soiffer RJ,Antin JH,Ritz J.Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.Blood. 2009 Apr 16;113(16):3865-74.
  • Patel NC,Chinen J,Rosenblatt HM,Hanson IC,Brown BS,Paul ME,Abramson SL,Ritz J,Shearer WT.Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.J Allergy Clin Immunol. 2008 Dec;122(6):1185-93.
  • Fonseca C,Soiffer R,Ho V,Vanneman M,Jinushi M,Ritz J,Neuberg D,Stone R,DeAngelo D,Dranoff G.Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.Blood. 2009 Feb 19;113(8):1681-8.
  • Stone RM,DeAngelo DJ,Janosova A,Galinsky I,Canning C,Ritz J,Soiffer RJ.Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission.Am J Hematol. 2008 Oct;83(10):771-7.
  • Ofran Y,Ritz J.Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation.Clin Cancer Res. 2008 Aug 15;14(16):4997-9. Review.
  • Steigman SA,Armant M,Bayer-Zwirello L,Kao GS,Silberstein L,Ritz J,Fauza DO.Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol.J Pediatr Surg. 2008 Jun;43(6):1164-9.
  • Armistead PM,Mohseni M,Gerwin R,Walsh EC,Iravani M,Chahardouli B,Rostami S,Zhang W,Neuberg D,Rioux J,Ghavamzadeh A,Ritz J,Antin JH,Wu CJ.Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.Exp Hematol. 2008 Sep;36(9):1205-15.
  • Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G.MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1285-90.
  • Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J, Alyea EP, Antin JH, Soiffer RJ.A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35.
  • Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, Antin JH, Ritz J.High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.Clin Cancer Res. 2007 Oct 15;13(20):6107-14.
  • Wu CJ, Gladwin M, Tisdale J, Hsieh M, Law T, Biernacki M, Rogers S, Wang X, Walters M, Zahrieh D, Antin JH, Ritz J, Krishnamurti L.Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis.Br J Haematol. 2007 Nov;139(3):504-7.
  • Armand P, Kim HT, Deangelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ.Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation.Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64.
  • Chiaretti S, Tavolaro S, Ghia EM, Ariola C, Matteucci C, Elia L, Maggio R, Messina M, Ricciardi MR, Vitale A, Ritz J, Mecucci C, Guarini A, Fo R.Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.Haematologica. 2007 May;92(5):619-26.
  • Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64.
  • Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ.Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55.
  • Bellucci R, Oertelt S, Gallagher M, Li S, Zorn E, Weller E, Porcheray F, Alyea EP, Soiffer RJ, Munshi NC, Gershwin ME, Ritz J.Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis.Blood. 2007 Mar 1;109(5):2001-7.
  • Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, Lai R, Ritz J, Krause DS, Chai L.SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.Blood. 2006 Oct 15;108(8):2726-35.
  • Mullally A, Ritz J.Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation.Blood. 2007 Feb 15;109(4):1355-62. Review.
  • Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, Frank DA, Ritz J.IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT dependent mechanism and induces the expansion of these cells in vivo.Blood. 2006 Sep 1;108(5):1571-9.
  • Zubair AC, Kao G, Daley H, Schott D, Freedman A, Ritz J.CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation.Cytotherapy. 2006;8(4):399-407.
  • Wu CJ, Ritz J.Induction of tumor immunity following allogeneic stem cell transplantation.Adv Immunol. 2006;90:133-73. Review.
  • Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E.Rituximab for steroid-refractory chronic graft-versus-host disease.Blood. 2006 Jul 15;108(2):756-62.
  • Chiaretti S, Li X, Gentleman R, Vitale A, Wang KS, Mandelli F, Fo R, Ritz J.Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation.Clin Cancer Res. 2005 Oct 15;11(20):7209-19.
  • Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM.Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.Blood. 2005 Dec 15;106(13):4389-96.
  • Wu CJ, Krishnamurti L, Kutok JL, Biernacki M, Rogers S, Zhang W, Antin JH, Ritz J.Evidence for ineffective erythropoiesis in severe sickle cell disease.Blood. 2005 Nov 15;106(10):3639-45.
  • Chiaretti S, Ritz J, Foa R.Genomic analysis in lymphoid leukemias.Rev Clin Exp Hematol. 2005 Jun;9(1):E3.
  • Tadesse MG, Ibrahim JG, Gentleman R, Chiaretti S, Ritz J, Foa R.Bayesian error-in-variable survival model for the analysis of GeneChip arrays.Biometrics. 2005 Jun;61(2):488-97.
  • Robertson MJ, Schacterle RS, Mackin GA, Wilson SN, Bloomingdale KL, Ritz J, Komaroff AL.Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression.Clin Exp Immunol. 2005 Aug;141(2):326-32.
  • Torelli GF, Guarini A, Porzia A, Chiaretti S, Tatarelli C, Diverio D, Maggio R, Vitale A, Ritz J, Foa R.FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia.Br J Haematol. 2005 Jul;130(1):43-50.
  • Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J.Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.Blood. 2005 Oct 15;106(8):2903-11.
  • Wu CJ, Biernacki M, Kutok JL, Rogers S, Chen L, Yang XF, Soiffer RJ, Ritz J.Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.Clin Cancer Res. 2005 Jun 15;11(12):4504-11.
  • Bellucci R, Alyea EP, Chiaretti S, Wu CJ, Zorn E, Weller E, Wu B, Canning C, Schlossman R, Munshi NC, Anderson KC, Ritz J.Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.Blood. 2005 May 15;105(10):3945-50.
  • Alyea EP, Kim HT, Ho VT, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ.Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients greater than fifty years of age.Blood. 2005 Feb 15;105(4):1810-4.
  • Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ, Antin JH, Ritz J.Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.Blood. 2005 Apr 1;105(7):2973-8.
  • DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.Clin Cancer Res. 2004 Aug 1;10(15):5065-71.
  • Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH.Safety and Efficacy of Denileukin Diftitox in Patients with Steroid Refractory Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Blood. 2004 Aug 15;104(4):1224-6.
  • Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer RJ, Antin JH, Ritz J.Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation.J Exp Med. 2004 Apr 19;199(8):1133-42.
  • Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J.Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.Transfusion. 2004 Feb;44(2):253-61.
  • Yan Y, Phan L, Yang F, Talpaz M, Yang Y, Xiong Z, Ng B, Timchenko NA, Wu CJ, Ritz J, Wang H, Yang XF.A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.J Immunol. 2004 Jan 1;172(1):651-60.
  • Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, Mandelli F, Ritz J, Foa R.Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival.Blood. 2004 Apr 1;103(7):2771-8.
  • Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.Bone Marrow Transplant. 2003 Dec;32(12):1145-51.
  • Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP, Dranoff G, Anderson KC, Munshi NC, Ritz J.Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.Blood. 2004 Jan 15;103(2):656-63.
  • Wu CJ, Hochberg EP, Rogers SA, Kutok JL, Biernacki M, Nascimento AF, Marks P, Bridges K, Ritz J.Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation.Exp Hematol. 2003 Oct;31(10):924-33.
  • Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J.Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.Blood. 2004 Jan 1;103(1):353-9.
  • Orsini E, Bellucci R, Alyea EP, Schlossman R, Canning C, McLaughlin S, Ghia P, Anderson KC, Ritz J.Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.Cancer Res. 2003 May 15;63(10):2561-8.
  • Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J.Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution.Transfusion. 2003 May;43(5):614-21.
  • Wu CJ, Neuberg D, Chillemi A, McLaughlin S, Hochberg EP, Galinsky I, DeAngelo D, Soiffer RJ, Alyea EP, Capdeville R, Stone RM, Ritz J.Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.Leuk Lymphoma. 2002 Dec;43(12):2281-9.
  • Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.Biol Blood Marrow Transplant. 2002;8(11):625-32.
  • Hochberg EP, Miklos DB, Neuberg D, Eichner DA, McLaughlin SF, Mattes-Ritz A, Alyea EP, Antin JH, Soiffer RJ, Ritz J.A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation.Blood. 2003 Jan 1;101(1):363-9.
  • Yang XF, Wu CJ, Chen L, Alyea EP, Canning C, Kantoff P, Soiffer RJ, Dranoff G, Ritz J.CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells.Cancer Res. 2002 Oct 1;62(19):5517-22.
  • Zorn E, Wang KS, Hochberg EP, Canning C, Alyea EP, Soiffer RJ, Ritz J.Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.Clin Cancer Res. 2002 Jul;8(7):2052-60.
  • Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS.Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.Br J Haematol. 2002 Jun;117(4):828-34.
  • Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, Canning C, Schlossman R, Soiffer RJ, Anderson KC, Ritz J.Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.Blood. 2002 Jun 15;99(12):4610-7.
  • Testa U, Torelli GF, Riccioni R, Muta AO, Militi S, Annino L, Mariani G, Guarini A, Chiaretti S, Ritz J, Mandelli F, Peschle C, Foa R.Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors.Blood. 2002 Jun 15;99(12):4634-7.
  • Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, Alyea EP, Yang J, Neuberg D, Mihm M, Dranoff G.ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.Proc Natl Acad Sci U S A. 2002 May 14;99(10):6919-24.
  • Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R, Fisher D, Gribben J, Ritz J, Soiffer R.Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation.Biol Blood Marrow Transplant. 2002;8(3):139-44.
  • Zaki MH, Wysocka M, Everetts SE, Wang KS, French LE, Ritz J, Rook AH.Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.J Invest Dermatol. 2002 Feb;118(2):366-71.
  • Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K.T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.Blood. 2001 Aug 15;98(4):934-9.
  • Hochberg EP, Chillemi AC, Wu CJ, Neuberg D, Canning C, Hartman K, Alyea EP, Soiffer RJ, Kalams SA, Ritz J.Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults.Blood. 2001 Aug 15;98(4):1116-21.
  • Yang XF, Wu CJ, McLaughlin S, Chillemi A, Wang KS, Canning C, Alyea EP, Kantoff P, Soiffer RJ, Dranoff G, Ritz J.CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7492-7.
  • Wang KS, Zorn E, Ritz J.Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation.Blood. 2001 Jun 15;97(12):3860-6.
  • Zorn E, Orsini E, Wu CJ, Stein B, Chillemi A, Canning C, Alyea EP, Soiffer RJ, Ritz J.A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.Transplantation. 2001 Apr 27;71(8):1131-7.
  • Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.J Clin Oncol. 2001 Feb 15;19(4):1152-9.
  • Mahajan S, Gollob JA, Ritz J, Frank DA.CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells.Exp Hematol. 2001 Feb;29(2):209-20.
  • Wu CJ, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B, Alyea EP, Soiffer RJ, Dranoff G, Ritz J.Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.J Clin Invest. 2000 Sep;106(5):705-14.
  • Orsini E, Alyea EP, Chillemi A, Schlossman R, McLaughlin S, Canning C, Soiffer RJ, Anderson KC, Ritz J.Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.Biol Blood Marrow Transplant. 2000;6(4):375-86.
  • Wang KS, Frank DA, Ritz J.Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4.Blood. 2000 May 15;95(10):3183-90.
  • Orsini E, Alyea EP, Schlossman R, Canning C, Soiffer RJ, Chillemi A, Neuberg D, Anderson KC, Ritz J.Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.Bone Marrow Transplant. 2000 Mar;25(6):623-32.
  • Wu CJ, Chillemi A, Alyea EP, Orsini E, Neuberg D, Soiffer RJ, Ritz J.Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism.Blood. 2000 Jan 1;95(1):352-9.
  • Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG.Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma.Blood. 1999 Nov 15;94(10):3325-33.
  • Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS.Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.J Clin Oncol. 1999 Oct;17(10):3128-35.
  • Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Jallow H, Kuhlman C, Ritz J, Freedman AS.Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.Biol Blood Marrow Transplant. 1999;5(4):262-8.
  • Borrego F, Robertson MJ, Ritz J, Pea J, Solana R.CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor.Immunology. 1999 May;97(1):159-65.
  • Frank DA, Mahajan S, Ritz J.Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.Nat Med. 1999 Apr;5(4):444-7.
  • Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA.The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation.J Immunol. 1999 Apr 15;162(8):4472-81.
  • Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ.Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.J Clin Oncol. 1999 Feb;17(2):561-8.
  • Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H, Marsh DJ, Ritz J, Freedman A, Stiles C, Eng C.PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies.Hum Mol Genet. 1999 Feb;8(2):185-93.
  • Robertson MJ, Cameron C, Atkins MB, Gordon MS, Lotze MT, Sherman ML, Ritz J.Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.Clin Cancer Res. 1999 Jan;5(1):9-16.
  • Wang KS, Ritz J, Frank DA.IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells.J Immunol. 1999 Jan 1;162(1):299-304.
  • Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML.Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.Clin Cancer Res. 1997 Mar;3(3):409-17.
  • Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J.Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.Clin Cancer Res. 1997 Jan;3(1):17-24.
  • Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J.Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.Clin Cancer Res. 1996 Mar;2(3):493-9.
  • Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ.Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation.Blood. 1998 Oct 15;92(8):2725-9.
  • Delabesse E, Bernard M, Meyer V, Smit L, Pulford K, Cayuela JM, Ritz J, Bourquelot P, Strominger JL, Valensi F, Macintyre EA.TAL1 expression does not occur in the majority of T-ALL blasts.Br J Haematol. 1998 Jul;102(2):449-57.
  • Gollob JA, Schnipper CP, Orsini E, Murphy E, Daley JF, Lazo SB, Frank DA, Neuberg D, Ritz J.Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.J Clin Invest. 1998 Aug 1;102(3):561-75.
  • Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, Schlossman RL, Bartlett-Pandite L, Kuhlman C, Murray C, Freeman A, Mauch P, Anderson KC, Nadler LM, Ritz J.CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.Bone Marrow Transplant. 1998 Jun;21(12):1177-81.
  • Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.Blood. 1998 May 15;91(10):3671-80.
  • Gollob JA, Murphy EA, Mahajan S, Schnipper CP, Ritz J, Frank DA.Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1.Blood. 1998 Feb 15;91(4):1341-54.
  • Voss SD, Daley J, Ritz J, Robertson MJ.Participation of the CD94 receptor complex in costimulation of human natural killer cells.J Immunol. 1998 Feb 15;160(4):1618-26.
  • Webb IJ, Soiffer RJ, Andersen JW, Cohen CA, Freeman A, Sugrue M, Ritz J, Anderson KC.In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation.Biol Blood Marrow Transplant. 1997 Nov;3(5):267-72.
  • Frank DA, Mahajan S, Ritz J.B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.J Clin Invest. 1997 Dec 15;100(12):3140-8.
  • Freedman A, Neuberg D, Mauch P, Gribben J, Soiffer R, Anderson K, Robertson M, Fisher DC, Schlossman R, Kroon M, Rhuda C, Kuhlman C, Ritz J, Nadler L.Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.Blood. 1997 Dec 15;90(12):4996-5001.
  • Weisdorf DJ, Billett AL, Hannan P, Ritz J, Sallan SE, Steinbuch M, Ramsay NK.Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia.Blood. 1997 Oct 15;90(8):2962-8.
  • Ida H, Robertson MJ, Voss S, Ritz J, Anderson P.CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells.J Immunol. 1997 Sep 1;159(5):2154-60.
  • Claret EJ, Alyea EP, Orsini E, Pickett CC, Collins H, Wang Y, Neuberg D, Soiffer RJ, Ritz J.Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion.J Clin Invest. 1997 Aug 15;100(4):855-66.
  • Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J.CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.Blood. 1997 Apr 15;89(8):3039-47.
  • Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.Biol Blood Marrow Transplant. 1997 Apr;3(1):11-7.
  • Gollob JA, Kawasaki H, Ritz J.Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression.Eur J Immunol. 1997 Mar;27(3):647-52.
  • Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J.Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.J Clin Oncol. 1997 Feb;15(2):723-34.
  • Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingeroth J, Ritz J.Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon.Transplantation. 1996 Nov 15;62(9):1358-60.
  • Gollob JA, Ritz J.CD2-CD58 interaction and the control of T-cell interleukin-12 responsiveness. Adhesion molecules link innate and acquired immunity.Ann N Y Acad Sci. 1996 Oct 31;795:71-81.
  • Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM.High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission.Blood. 1996 Oct 1;88(7):2780-6.
  • Pignata C, Sanghera JS, Soiffer RJ, Chartier S, Eder M, Pelech SL, Ritz J.Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation.Blood. 1996 Sep 15;88(6):2334-41.
  • Gollob JA, Li J, Kawasaki H, Daley JF, Groves C, Reinherz EL, Ritz J.Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12.J Immunol. 1996 Sep 1;157(5):1886-93.
  • Boussiotis VA, Pardo NA, Collins H, Houghton A, Ritz J, Nadler LM, Soiffer RJ.R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy.Eur J Immunol. 1996 Sep;26(9):2149-54.
  • Nguyen PL, Harris NL, Ritz J, Robertson MJ.Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.Am J Pathol. 1996 Mar;148(3):847-53.
  • Gollob JA, Li J, Reinherz EL, Ritz J.CD2 regulates responsiveness of activated T cells to interleukin 12.J Exp Med. 1995 Sep 1;182(3):721-31.
  • Frank DA, Robertson MJ, Bonni A, Ritz J, Greenberg ME.Interleukin 2 signaling involves the phosphorylation of Stat proteins.Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7779-83.
  • Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H, Ritz J.Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells.Leuk Lymphoma. 1995 Mar;17(1-2):51-61.
  • Soiffer RJ, Murray C, Ritz J, Phillips N, Jacobsohn D, Chartier S, Ambrosino DM.Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations.Blood. 1995 Feb 15;85(4):925-8.
  • Kameoka J, Sato T, Torimoto Y, Sugita K, Soiffer RJ, Schlossman SF, Ritz J, Morimoto C.Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation.Blood. 1995 Feb 15;85(4):1132-7.
  • Roy DC, Perreault C, Blanger R, Gyger M, Le Houillier C, Blttler WA, Lambert JM, Ritz J.Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.J Clin Immunol. 1995 Jan;15(1):51-7.
  • Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, Finberg R.Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial.J Clin Oncol. 1995 Jan;13(1):239-50.
  • Soiffer RJ, Alyea EP, Ritz J.Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation.J Clin Apheresis. 1995;10(3):139-43.
  • Pichert G, Alyea EP, Soiffer RJ, Roy DC, Ritz J.Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.Blood. 1994 Oct 1;84(7):2109-14.
  • Soiffer RJ, Murray C, Gonin R, Ritz J.Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.Blood. 1994 Aug 1;84(3):964-71.
  • Sugita K, Nojima Y, Tachibana K, Soiffer RJ, Murray C, Schlossman SF, Ritz J, Morimoto C.Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation.J Clin Invest. 1994 Aug;94(2):481-8.
  • Nakarai T, Robertson MJ, Streuli M, Wu Z, Ciardelli TL, Smith KA, Ritz J.Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.J Exp Med. 1994 Jul 1;180(1):241-51.
  • Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA.CD antigens 1993.Blood. 1994 Feb 15;83(4):879-80.
  • Ritz J.Tumor immunity: will new keys unlock the door?.J Clin Oncol. 1994 Feb;12(2):237-8.
  • Robertson MJ, Roy DC, Stone RM, Ritz J.Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia.Prog Clin Biol Res. 1994;389:47-63.
  • Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Ariniello P, Coral F, Ritz J.Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.Int J Cancer Suppl. 1994;8:57-9.
  • Robertson MJ, Ritz J.Prognostic significance of the surface antigens expressed by leukemic cells.Leuk Lymphoma. 1994;13 Suppl 1:15-22.
  • Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J.Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies.Blood. 1993 Nov 1;82(9):2790-6.
  • Sugita K, Robertson MJ, Torimoto Y, Ritz J, Schlossman SF, Morimoto C.Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells.J Immunol. 1992 Aug 15;149(4):1199-203.
  • Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Herrmann SH, Ritz J.Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.J Exp Med. 1992 Mar 1;175(3):779-88.
  • Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blttler WA.Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.Blood. 1992 Feb 1;79(3):576-85.
  • Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J.Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.Blood. 1992 Jan 15;79(2):517-26.
  • Tycko B, Ritz J, Sallan S, Sklar J.Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease.Blood. 1992 Jan 15;79(2):481-8.
  • Baume DM, Robertson MJ, Levine H, Manley TJ, Schow PW, Ritz J.Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.Eur J Immunol. 1992 Jan;22(1):1-6.
  • Delage R, Soiffer RJ, Dear K, Ritz J.Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.Blood. 1991 Nov 15;78(10):2759-67.
  • Robertson MJ, Ritz J.Biology and clinical relevance of human natural killer cells.Blood. 1990 Dec 15;76(12):2421-38.
  • Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J.Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis.J Immunol. 1990 Nov 15;145(10):3194-201.
  • Jochelson M, Tarbell NJ, Freedman AS, Rabinowe SN, Takvorian T, Soiffer R, Anderson K, Ritz J, Nadler LM.Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma.Bone Marrow Transplant. 1990 Nov;6(5):329-31.
  • Soiffer RJ, Bosserman L, Murray C, Cochran K, Daley J, Ritz J.Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation.Blood. 1990 May 15;75(10):2076-84.
  • Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, Ritz J.Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.J Exp Med. 1990 May 1;171(5):1509-26.
  • Anderson P, Caligiuri M, O'Brien C, Manley T, Ritz J, Schlossman SF.Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells.Proc Natl Acad Sci U S A. 1990 Mar;87(6):2274-8.
  • Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC, Freedman AS, Nadler LM, Ritz J.Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium.Blood. 1990 Jan 1;75(1):296-304.
  • Anderson P, Caligiuri M, Ritz J, Schlossman SF.CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex.Nature. 1989 Sep 14;341(6238):159-62.
  • Schmidt RE, Michon JM, Woronicz J, Schlossman SF, Reinherz EL, Ritz J.Enhancement of natural killer function through activation of the T11 E rosette receptor.J Clin Invest. 1987 Jan;79(1):305-8.
  • Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J.A subset of natural killer cells in peripheral blood displays a mature T cell phenotype.J Exp Med. 1986 Jul 1;164(1):351-6.
  • Hercend T, Takvorian T, Nowill A, Tantravahi R, Moingeon P, Anderson KC, Murray C, Bohuon C, Ythier A, Ritz J.Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation.Blood. 1986 Mar;67(3):722-8.
  • Schmidt RE, MacDermott RP, Bartley G, Bertovich M, Amato DA, Austen KF, Schlossman SF, Stevens RL, Ritz J.Specific release of proteoglycans from human natural killer cells during target lysis.Nature. 1985 Nov 21-27;318(6043):289-91.
  • Siliciano RF, Pratt JC, Schmidt RE, Ritz J, Reinherz EL.Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein.Nature. 1985 Oct 3-9;317(6036):428-30.
  • Ritz J, Campen TJ, Schmidt RE, Royer HD, Hercend T, Hussey RE, Reinherz EL.Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones.Science. 1985 Jun 28;228(4707):1540-3.
  • Hercend T, Griffin JD, Bensussan A, Schmidt RE, Edson MA, Brennan A, Murray C, Daley JF, Schlossman SF, Ritz J.Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.J Clin Invest. 1985 Mar;75(3):932-43.
  • Hercend T, Reinherz EL, Meuer S, Schlossman SF, Ritz J.Phenotypic and functional heterogeneity of human cloned natural killer cell lines.Nature. 1983 Jan 13;301(5896):158-60.